Table 2.
Baseline SBP Category | Baseline to 1 Month |
Baseline to 6 Months |
||||
---|---|---|---|---|---|---|
Placebo | MRA | Difference | Placebo | MRA | Difference | |
≤105 mm Hg | 8.9 ± 15.1 | 6.1 ± 13.5 | 2.8 | 12.3 ± 16.2 | 9.6 ± 15.1 | 2.8 |
>105 to ≤115 mm Hg | 4.2 ± 13.3 | 2.5 ± 14.5 | 1.7 | 6.6 ± 16.4 | 4.8 ± 15.9 | 1.7 |
>115 to ≤125 mm Hg | 0.9 ± 13.1 | 0.2 ± 14.5 | 0.7 | 2.9 ± 15.0 | 2.4 ± 15.8 | 0.4 |
>125 to ≤135 mm Hg | −3.1 ± 14.3 | −4.9 ± 13.4 | 1.8 | −0.9 ± 16.4 | −3.7 ± 14.0 | 2.9 |
>135 mm Hg | −10.0 ± 16.6 | −11.9 ± 17.7 | 1.8 | −9.3 ± 18.6 | −13.0 ± 18.0 | 3.6 |
Overall | −0.5 ± 15.9 | −2.4 ± 16.3 | 1.9 | 1.4 ± 18.1 | −1.2 ± 17.9 | 2.6 |
Values are mean ± SD changes in SBP.
MRA = mineralocorticoid receptor antagonist; SBP = systolic blood pressure.